The diverse application potential of metal-organic framework (MOF) materials are currently limited by their challenging and complicated preparation processes. In this study, we successfully developed a novel strategy for the rapid synthesis of a sustainable MOF composite membrane under neutral conditions with improved physicochemical and antibacterial properties. Our reaction pipeline comprised visible light that induced the production of reactive oxygen species (ROS) from ZIF-8 particles, which facilitated the rapid oxidative polymerization of dopamine to polydopamine. The physicochemical properties of the composite membrane were assessed using imaging methods, including scanning and transmission electron microscopy, X-ray photoelectron spectrometry, and nitrogen adsorption/desorption; its antibacterial effects against Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa were measured using optical densitometry. The bactericidal potency of the synthesized membrane was >99% against all tested strains under the conditions of simulated sunlight. Moreover, the composite membrane retained its structural integrity and antibacterial effect after multiple cycles of use and recovery, showcasing remarkable stability. Overall, this study displays a ROS-mediated method for the rapid preparation of sustainable MOF composite membranes under neutral conditions with optimal physicochemical characteristics, antibacterial properties, and performance. Our study provides insights into the use of membrane materials as design platforms for a range of diverse practical applications.

In this study, we constructed a linear antibody–drug conjugate (ADC), 7300-LP1003, by coupling the camptothecin derivative 095 to a linker through an ether bond. In vitro enzyme experiments indicated that LP1003 releases 095 through the action of tissue cathepsin B. Therefore, we introduced lysine pairs with different water-soluble substituents to further modify the linker and synthesized side-chain ADCs 7300-LP3004 and 7300-LP2004, modified by polysarcosine and polyethylene glycol, respectively. In vitro experiments showed that, after incubation at 55 °C in phosphate-buffered saline for 48 h, 7300-LP3004 aggregation was 45.24%, which was significantly lower than that of 7300-LP1003 (77.14%). Cell cytotoxicity assays demonstrated that the side-chain ADCs, 7300-LP3004 and 7300-LP2004, exhibited significantly higher activity (IC50 values of 39.74 nM and 32.17 nM, respectively) compared to the linear ADC and 7300-Deruxtecan (IC50 of 186.5 nM and 124.5 nM, respectively). In the subcutaneous model of SHP-77 NOD scid gamma mice, when the ADC dose was 5 mg/kg, 7300-LP3004 showed the highest tumor inhibition rate with a tumor growth inhibition (TGI) of 106.09%, which was superior to that of the positive control 7300-Deruxtecan, which had a TGI of 103.95%. In conclusion, 7300-LP3004 demonstrated strong antitumor activity and high physicochemical stability, highlighting the need for further research and development of ADC drugs.